TICKERNERD
Menu
LENZLENZHealthcare · Biotechnology

LENZ Stock Forecast: LENZ Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$3.21

The 7 Wall Street analysts covering LENZ Therapeutics, Inc. hold a median 12-month price target of $10 — +211.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$99.0M
Ticker Nerd rank
22/ 100
Median analyst target
$10
Analysts covering
7
Revenue$5.5M+9.7% y/y
Operating income−$34.2M
Net income−$31.9M
Free cash flow−$38.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

LENZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LENZ Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
74
Volatility
60
Revisions
54
Quality
48
Accruals
47
Issuance
39
Growth
25
Value
9
Momentum
1

Size (74): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LENZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LENZ, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $5Median $10High $50

The green dot is the last close — the median target sits +211.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
21 Oct 2026TD CowenMaintainsBuy$60 → $50
19 Oct 2026Piper SandlerMaintainsNeutral$7.00 → $5.00
12 Aug 2026Piper SandlerMaintainsNeutral$12 → $7.00
12 Aug 2026Piper SandlerMaintainsNeutral—
7 July 2026HC Wainwright & Co.ReiteratesBuy$38
7 July 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026CitigroupMaintainsBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Piper SandlerDowngradeNeutral—
21 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026CitigroupMaintainsBuy—
25 Mar 2026B of A SecuritiesMaintainsBuy—
20 Oct 2025Raymond JamesReiteratesOutperform—
10 Oct 2025Piper SandlerMaintainsOverweight—
1 Aug 2025CitigroupMaintainsBuy—
1 Aug 2025HC Wainwright & Co.MaintainsBuy—
31 July 2025CitigroupMaintainsBuy—
31 July 2025Raymond JamesMaintainsOutperform—
28 July 2025HC Wainwright & Co.MaintainsBuy—
8 May 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LENZ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

LENZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
2
Fundamentals

LENZ Therapeutics, Inc. (LENZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.0×

Cheaper than 15% of US stocks

Price / sales
4.6×

Cheaper than 25% of US stocks

Price / book
0.5×

Cheaper than 84% of US stocks

EV / EBITDA
0.9×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
9.7%

Higher than 53% of US stocks

Earnings growth (YoY)
9.7%

Higher than 48% of US stocks

Gross margin
94.9%

Higher than 98% of US stocks

Operating margin
−622.9%

Higher than 7% of US stocks

Net margin
97.8%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−59.2%

Higher than 19% of US stocks

Return on assets
−37.4%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

LENZ Therapeutics, Inc. (LENZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LENZ Therapeutics, Inc. has a market value of $99.0M and an enterprise value of −$120.5M.

  • Revenue in the twelve months to 30 June 2026: $21.5M. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: −$126.0M, a −586.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.09.

  • Free cash flow in the twelve months to 30 June 2026: −$114.4M.

  • Shares outstanding: 31.4M.

  • Trailing P/E: 48.0×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • LENZ Therapeutics, Inc. employs 152 people — $141K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

LENZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LENZLENZ Therapeutics, Inc.$99.0M22
UNCYUnicycive Therapeutics, Inc.$100.4M43
VTVTvTv Therapeutics, Inc.$101.3M77
PMNProMIS Neurosciences, Inc.$99.3M27
ENGNenGene Therapeutics, Inc.$102.0M18
GNLXGenelux Corp.$98.8M18
VANIVivani Medical, Inc.$102.8M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LENZ Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LENZ news & analysis

LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript

Seeking Alpha · 29 Oct 2026neutral

Seeking Alpha published a transcript of LENZ Therapeutics’ Q3 2026 earnings call, held October 29, 2026. The excerpt lists company representatives and participating analysts but provides no discussion of results or business updates.

Why it matters — The transcript gives LENZ watchers a record of the quarterly call, though the supplied excerpt does not contain substantive details about the company’s performance.

LENZ Therapeutics Q3 Earnings Call Highlights

MarketBeat · 29 Oct 2026positive

LENZ Therapeutics reported Q3 2026 product revenue of $2.6 million, up 50% sequentially. Prescriptions for VIZZ increased following expanded national advertising and the launch of a telehealth channel.

Why it matters — The results provide an update on VIZZ prescriptions and product revenue after the company expanded its advertising and telehealth access.

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research · 28 Oct 2026negative

LENZ Therapeutics reported a quarterly loss of $0.99 per share, compared with the consensus estimate of a $0.97 loss and a loss of $0.59 per share a year earlier.

Why it matters — The result shows LENZ's quarterly per-share loss was larger than analysts expected and than the loss reported a year ago.

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

GlobeNewsWire · 28 Oct 2026positive

LENZ Therapeutics reported that Q3 2026 VIZZ product sales increased 50% from the prior quarter, with momentum continuing into Q4 amid broader consumer awareness and increased telehealth adoption. The headline also announces a strategic reorganization focused on consumer marketing and a CEO succession.

Why it matters — The sales update and organizational changes provide LENZ watchers with information about product momentum and the company’s strategic and leadership direction.

FAQ

Frequently asked questions about LENZ stock

What is the LENZ stock price forecast for 2026-2027?

The 7 Wall Street analysts covering LENZ Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $5 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LENZ stock a buy right now?

Of the 7 analysts covering LENZ Therapeutics, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENZ Therapeutics, Inc. 22 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LENZ?

As at 28 Oct 2026, LENZ Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).

Will LENZ stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +211.5% from the last close, and Ticker Nerd's factor model ranks LENZ Therapeutics, Inc. 22 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LENZ stock forecast for 2030?

No analyst covering LENZ Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LENZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $50 over the next 12 months.

What does LENZ Therapeutics, Inc. do?

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision.

What is the latest news on LENZ?

The most recent item we track (Seeking Alpha, 29 Oct 2026): "LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of LENZ Therapeutics’ Q3 2026 earnings call, held October 29, 2026. The excerpt lists company representatives and participating analysts but provides no discussion of results or business updates.

Company

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision. The company develops eye-care therapies designed for convenient daily use, with an emphasis on preservative-free, single-use formulations that support patient adherence and ease of administration. LENZ Therapeutics serves the prescription eye-care market and concentrates on addressing a common vision condition affecting adults worldwide. Headquartered in Solana Beach, California, the company plays a specialized role in the broader ophthalmology and biopharmaceutical sectors by bringing non-surgical treatment options to market for presbyopia management.

CEO Mr. Evert B. Schimmelpennink · 152 employees · United States · https://www.lenz-tx.com